Stockreport

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes [Yahoo! Finance]

AngioDynamics, Inc.  (ANGO) 
Last angiodynamics, inc. earnings: 4/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.angiodynamics.com/investor-relations
PDF The RECOVER-AV trial is designed to evaluate the safety and efficacy of AlphaVac for the treatment of acute, intermediate-risk PE to support its adoption in the Europea [Read more]